Breast screening
Exam Tips
- In UK exams, quote programme basics accurately: routine 3-yearly mammography invitations from age 50 to before 71, with self-referral possible above routine age limits.
- A high-yield counselling station point is balanced consent: discuss both mortality benefit and harms (overdiagnosis, false positives, interval cancers) using absolute framing when possible.
- Differentiate screening from symptomatic pathways: a normal screen does not exclude cancer if red-flag symptoms arise.
- Remember core exam concept: screen-detected cancers are often non-palpable and may appear as microcalcifications or architectural distortion on mammography.
- For image interpretation revision, review standard mammographic examples of spiculated mass and malignant microcalcification patterns in a breast imaging atlas figure set.
Definition
Breast screening is a population-level preventive programme that uses routine mammography to detect breast cancer before clinical symptoms develop, mainly in women at average risk. In the UK NHS programme, invitations are generally every 3 years from age 50 up to the 71st birthday, with earlier or additional imaging for selected higher-risk groups and optional self-referral above routine age limits.
Pathophysiology
Screening targets the preclinical detectable phase of breast cancer, when lesions such as ductal carcinoma in situ (DCIS) or small invasive tumours are visible radiographically but not yet palpable. Mammography identifies features including microcalcifications, architectural distortion, and small masses; detecting disease at lower tumour burden reduces nodal spread and supports breast-conserving treatment. Benefit depends on tumour biology and lead-time, while harms arise from overdiagnosis (indolent lesions that may never cause symptoms), false positives, and false reassurance from interval cancers.
Risk Factors
- Female sex and increasing age
- Family history of breast/ovarian cancer (including known BRCA-associated families)
- Personal history of atypical hyperplasia, LCIS, or prior chest irradiation
- Hormonal/reproductive factors (early menarche, late menopause, nulliparity, later first pregnancy)
- Lifestyle factors (alcohol excess, obesity after menopause, physical inactivity)
- Higher mammographic density (reduced mammographic sensitivity)
Clinical Features
Symptoms
- Usually asymptomatic at time of routine screening
- If interval cancer develops: new breast lump, unilateral nipple change, skin tethering, bloody nipple discharge
- Anxiety, distress, or uncertainty after recall for further assessment
Signs
- No abnormal findings on clinical examination in many screen-detected cancers
- Mammographic signs: clustered pleomorphic microcalcifications, spiculated mass, focal asymmetry, architectural distortion
- Advanced clinical signs (late/interval presentation): peau d'orange, nipple inversion, palpable axillary nodes
Investigations
Management
Lifestyle Modifications
- Provide balanced shared decision-making: explain mortality benefit and potential harms (overdiagnosis, false positives, interval cancers)
- Encourage attendance at scheduled 3-yearly invitations and prompt self-referral if above routine invitation age
- Advise urgent symptomatic presentation pathways regardless of last screening result
- Risk reduction counselling: limit alcohol, maintain healthy weight, increase physical activity
Pharmacological Treatment
Analgesia for post-mammography discomfort (if needed)
- Paracetamol 1 g orally every 4-6 hours when required (maximum 4 g/day)
- Ibuprofen 200-400 mg orally up to three times daily with food (maximum OTC 1.2 g/day)
Not routine treatment for screening itself. Avoid ibuprofen in active peptic ulcer disease, severe renal impairment, NSAID hypersensitivity/asthma precipitated by NSAIDs, and in late pregnancy; check anticoagulant use and GI risk.
Surgical / Interventional
- Image-guided vacuum-assisted biopsy/excision for selected screen-detected lesions
- Definitive surgery after confirmed malignancy (breast-conserving surgery or mastectomy, with sentinel node procedures as indicated)
Complications
- Overdiagnosis and overtreatment of biologically indolent disease
- False-positive recalls leading to additional imaging/biopsy with benign outcomes
- False-negative results with delayed diagnosis (interval cancer)
- Pain/discomfort during mammography
- Psychological morbidity (short-term anxiety, persistent cancer worry in some patients)
Prognosis
At programme level, screening is associated with improved breast-cancer outcomes through earlier stage detection and an estimated relative breast-cancer mortality reduction of about 20% in invited populations. UK estimates suggest approximately one breast-cancer death prevented per 235 women invited (or per 180 attending), balanced against non-trivial overdiagnosis risk and recall-related harms.
Sources & References
✅NICE Guidelines(1)
- Breast screening[overview]
📖Textbook References(4)
- Netter F. Netter Atlas of Human Anatomy. A Systems Approach 8ed 2022.pdf(pp. 36)[context]
- Netter F. Netter Atlas of Human Anatomy. Classic Regional Approach 8ed 2022.pdf(pp. 10)[context]
- _OceanofPDF.com_Netters_Anatomy_-_8th_edition_-_Frank_H_Netter_MD.pdf(pp. 36)[context]
- [Williams, Bailey and Love's Short Practice of Surgery] Norman Williams, Christopher Bulstrode, P Ronan O'Connell - Bailey & Love's Short Practice of Surgery 26E (2013, CRC Press) - libgen.li.pdf(pp. 834)[context]